Letter to the editor: consideration on: 'What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?' by Reid I.R.
作者信息
Di Monaco Marco, Castiglioni Carlotta, Bardesono Francesca
机构信息
Osteoporosis Research Center, San Camillo Foundation, Turin, Italy.
出版信息
Expert Opin Drug Saf. 2023 Jan;22(1):103-104. doi: 10.1080/14740338.2023.2173737. Epub 2023 Jan 29.
Abstract
摘要
相似文献
1
Letter to the editor: consideration on: 'What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?' by Reid I.R.
Expert Opin Drug Saf. 2023 Jan;22(1):103-104. doi: 10.1080/14740338.2023.2173737. Epub 2023 Jan 29.
2
What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?接受罗莫索单抗治疗的骨质疏松症患者发生心血管事件的风险是什么？
Expert Opin Drug Saf. 2022 Dec;21(12):1441-1443. doi: 10.1080/14740338.2022.2160445. Epub 2022 Dec 27.
3
Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk.罗莫佐单抗治疗女性骨质疏松症：疗效、安全性和心血管风险。
Womens Health (Lond). 2022 Jan-Dec;18:17455057221125577. doi: 10.1177/17455057221125577.
4
Cardiovascular Safety and Sclerostin Inhibition.心血管安全性与硬骨素抑制
J Clin Endocrinol Metab. 2021 Jun 16;106(7):1845-1853. doi: 10.1210/clinem/dgab193.
5
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.罗莫佐单抗或阿仑膦酸钠用于预防骨质疏松症女性骨折。
N Engl J Med. 2017 Oct 12;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11.
6
Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab.阿仑膦酸钠和罗莫佐单抗试验中心血管事件发生率差异的解释。
Osteoporos Int. 2020 Jun;31(6):1019-1021. doi: 10.1007/s00198-020-05379-z. Epub 2020 Apr 4.
7
Amgen and UCB announce increased cardiovascular risk in patients receiving romosozumab, an anti-sclerotin antibody.
Rheumatology (Oxford). 2017 Aug 1;56(8):e21. doi: 10.1093/rheumatology/kex244.
8
Romosozumab: A Review in Postmenopausal Osteoporosis.罗莫佐单抗：用于绝经后骨质疏松症的研究综述。
Drugs Aging. 2020 Nov;37(11):845-855. doi: 10.1007/s40266-020-00793-8.
9
Romosozumab (Evenity) for postmenopausal osteoporosis.罗莫单抗（艾地骨化醇）用于绝经后骨质疏松症。
Med Lett Drugs Ther. 2019 Jun 3;61(1573):83-86.
10
[Sequential treatment of osteoporosis with anti-sclerostin.].[抗硬化蛋白序贯治疗骨质疏松症。]
Clin Calcium. 2019;29(3):363-369. doi: 10.20837/4201903363.
Zotero 插件